Because high PRMT3 expression inhibited anti-tumor immunity and efficacy of ICB by methylating HSP60, our findings suggested that PRMT3 might be an important regulator of secondary immunotherapy resistance in HCC. The gene discussed is HSPD1; the disease is hepatocellular carcinoma.